Send me real-time posts from this site at my email

Watchlist Update: 4-30-2019 - IMMU - Immunomedics - Analyst Comments

Immunomedics analyst commentary at H.C. Wainwright

Immunomedics pullback brings favorable entry point, says H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju says the recent weakness in shares of Immunomedics creates a favorable entry point. The analyst views the company's licensing agreement with China's Everest Medicines as favorable and upped his price target for the shares to $29 from $28. Everest's expertise around development, regulatory affairs, and commercialization in Asian markets should enable IMMU-132 to enter those markets in the most expeditious timeframe, Selvaraju tells investors in a research note. He reiterates a Buy rating on Immunomedics.

Read more at:  (source)   $IMMU

On our trading list, a biotech with good potential.

$IMMU, Immunomedics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or comments.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue